Direct answer
Professional assessment, CBT, manageable activity and insomnia treatment are useful parts of care. Exercise, diet, mindfulness and social-relationship evidence has important limits. Supplements remain adjuncts with uncertain benefits and product-specific interactions.
- A 2024 BMJ network meta-analysis of 218 studies (14,170 participants) found average reductions in depression symptoms with walking/jogging, yoga, strength training, mixed aerobic activity and tai chi/qigong. Certainty was low or very low, and only one study had low risk of bias. Source.
- CBT is a core professional treatment for many anxiety and depression presentations. APA describes improved functioning and coping skills, while treatment choice depends on diagnosis, severity, preferences and access. Source 1. Source 2. Source 3.
- WHO recommends 150–300 minutes of moderate aerobic activity weekly (or 75–150 vigorous) plus strength training 2+ days/week as the baseline prevention target.
- A meta-analysis found nearly 70% of people with mental disorders report sleep difficulties, and CBT-I produces medium-to-large insomnia improvements even in people with comorbid depression, PTSD, or alcohol dependency.
- Mindfulness meditation shows only moderate evidence for anxiety/depression and is not proven superior to active treatments like exercise, medication, or CBT (JAMA Internal Medicine systematic review).
Evidence-based mental health guide · Global audience
Stress, anxiety, and depression are not solved by one supplement or one habit; the strongest plan combines professional care when symptoms are severe, CBT-style psychological skills, regular physical activity, sleep repair, supportive relationships, and cautious use of supplements only when benefits outweigh interaction risks. Severe depression, suicidal thoughts, panic that limits daily life, psychosis, mania, substance dependence, or inability to work, eat, sleep, study, or care for dependents should be treated as a medical priority, not a self-care project; WHO notes that effective treatment exists for mild, moderate, and severe depression, and anxiety disorders also have highly effective treatments (WHO depression fact sheet, WHO anxiety disorders fact sheet).
If there is any risk of suicide, self-harm, violence, psychosis, mania, severe withdrawal, or inability to stay safe, seek urgent local emergency help or crisis support immediately. Depression can lead to suicide, and WHO reported an estimated 727,000 suicide deaths in 2021 (WHO depression fact sheet).
Table of contents
- Evidence summary
- Stress, anxiety, and depression are related, not identical
- When to seek professional care
- The prevention and management stack
- CBT and psychological therapies
- Medication: when it belongs in the plan
- Supplements: useful adjuncts, not replacements
- All forms and types of support
- What works and what does not
- Risks and all side effects
- All interactions
- Frequently asked questions
- Sources
Evidence summary
| Claim | Evidence | Funding / conflict tracing | Verdict |
|---|---|---|---|
| Anxiety and depression are common, treatable medical conditions. | WHO reports 470 million people had anxiety disorders in 2023 and an estimated 5.2% of adults experienced depression in 2023; effective treatments exist for anxiety and for mild, moderate and severe depression. | WHO is a multilateral public-health body; no supplement or therapy product funder is attached to these fact sheets. | Strong WHO anxiety / WHO depression Source 1 Source 2 |
| CBT is a core professional treatment for anxiety and depression. | APA describes CBT as effective for depression, anxiety disorders, severe mental illness, and other problems, with many studies showing improved functioning and quality of life. | APA is a professional psychology organization; it may benefit from psychotherapy credibility, so claims are cross-checked against WHO statements that psychological treatment exists. | Strong APA CBT overview |
| Exercise reduces depression and anxiety symptoms for many adults. | A 2023 umbrella review of 97 reviews and more than 128,119 participants found median medium depression/anxiety symptom effects, but 77 reviews had critically low methodological quality; Cochrane reports a possible depression benefit. | The umbrella review disclosed Australian NHMRC/MRFF support and no competing interests. This does not establish independence of every underlying trial; incomplete Cochrane trial funding remains unknown. | Useful adjunct; variable certainty Source 1 Source 2 |
| Mindfulness meditation can reduce psychological stress symptoms, but it is not clearly superior to active treatments. | JAMA Internal Medicine systematic review found moderate evidence for anxiety and depression improvements and no evidence that meditation programs beat active treatments such as drugs, exercise, or behavioral therapies. | U.S. AHRQ-funded review (HHSA290200710061), with no conflicts reported. Small, heterogeneous trials and limited harm monitoring constrain conclusions. | Moderate adjunct Goyal et al. Source |
| Sleep treatment matters because insomnia commonly co-occurs with mental disorders. | CBT-I improved insomnia and pooled mental-health symptoms after treatment and at follow-up; diagnosis-specific pooled follow-up benefits were not significant. It complements treatment of the psychiatric disorder. | The full review reports no external funding and no author conflicts; included-trial financing was not systematically verified. | Strong for insomnia symptoms CBT-I meta-analysis Source |
| Dietary improvement may help depressive symptoms, but it is not a stand-alone cure. | SMILES RCT found greater MADRS improvement with dietary support than social-support control; a 2019 meta-analysis of 16 RCTs found dietary interventions reduced depressive symptoms but not anxiety. | SMILES reported an Australian NHMRC grant, Woolworths food vouchers, Village cinema vouchers, Carman’s muesli bars and Meat and Livestock Australia support for its biochemistry data, alongside author commercial relationships; the 2019 meta-analysis disclosed a Blackmores Institute fellowship for its lead author alongside public fellowships and multiple author relationships with food, supplement and pharmaceutical companies. Diet findings are useful context, with these conflicts disclosed. | Moderate for depression support SMILES RCT / diet meta-analysis |
| Social relationships are associated with health outcomes; this mortality review does not test a depression or anxiety intervention. | A PLOS Medicine meta-analysis found stronger social relationships were associated with improved survival and effects comparable with established mortality risk factors. | The original PLOS review reports BYU Department of Gerontology grants and a TP Industrial, Inc grant to one author. Authors declared no competing interests and reported no funder role; grant amounts and ultimate backers were not established. Original funding declaration. | Observational mortality association; indirect for mood PLOS Medicine meta-analysis |
| St John’s wort can help mild-to-moderate depression but has serious drug interactions. | Cochrane found St John’s wort extracts superior to placebo and similarly effective to standard antidepressants in trials, while NCCIH warns interactions with antidepressants and serotonin-related drugs can be serious. | Cochrane public summary does not show full funding for every included trial; NCCIH is a U.S. government health-information source with no St John’s wort sales incentive. | Works for some; high interaction risk Cochrane St John’s wort / NCCIH St John’s wort |
| Omega-3, magnesium, vitamin D, ashwagandha, L-theanine, and saffron have different evidence levels and cannot replace care for severe symptoms. | Cochrane says omega-3 evidence for major depression is not high-certainty; magnesium evidence for anxiety is suggestive but poor quality; vitamin D3 did not prevent depression in VITAL-DEP; NCCIH says some ashwagandha preparations may help stress and insomnia; L-theanine systematic review suggests 200–400 mg/day may reduce stress/anxiety under stressful conditions; saffron meta-analyses show promising depression effects but need larger independent trials. | Sources include government reviews, Cochrane and academic reviews with differing conflicts. Sanofi financed the magnesium review’s initial search, supplied three unpublished studies, and had an author on its advisory board. The L-theanine author manuscript reports government research-training and Dementia Australia scholarships; no conflict declaration was located. The saffron repository names Hungarian public research grants and an Academy scholarship; complete included-trial finances remain unverified. Supplement claims remain limited to adjunct context. | Mixed by ingredient Cochrane omega-3 / magnesium review / VITAL-DEP / NCCIH ashwagandha / L-theanine review / saffron meta-analysis |
Stress, anxiety, and depression are related, not identical
Stress is the body-and-mind response to demands or threats, and APA notes that chronic stress can affect multiple systems including musculoskeletal, respiratory, cardiovascular, endocrine, gastrointestinal, nervous, and reproductive systems (APA stress effects). Anxiety becomes a disorder when fear or worry is intense, excessive, hard to control, persistent for months, distressing, and impairing, and WHO lists symptoms such as trouble concentrating, irritability, nausea, palpitations, sweating, trembling, poor sleep, and panic or doom feelings (WHO anxiety disorders fact sheet). Depression is more than a bad mood: WHO describes depression as depressed mood or loss of pleasure/interest for long periods, with symptoms such as poor concentration, guilt, hopelessness, thoughts of death or suicide, sleep or appetite change, and low energy (WHO depression fact sheet).
Stress, anxiety, and depression decision map
Read the practical summary
| Pattern | Core features | Action |
|---|---|---|
| Stress | Triggered by demands; body tension and fatigue; often improves when load changes; chronic stress can affect many body systems according to APA. | Reduce load where possible, add recovery, use coping skills, seek help if persistent or impairing. |
| Anxiety disorder | Excessive fear or worry, difficult to control for months, distressing, avoidant, and impairing according to WHO. | CBT/exposure-based therapy and medical evaluation when symptoms limit daily life. |
| Depression | Low mood or loss of interest most days, often with sleep, appetite, energy, guilt, concentration, hopelessness, or suicidal thoughts according to WHO. | Professional assessment; urgent support for self-harm thoughts or severe impairment. |
When to seek professional care
Professional care belongs early when symptoms persist, impair daily functioning, or create safety risk, because WHO states anxiety disorders and depression have effective treatments but many people do not receive care (WHO anxiety disorders fact sheet, WHO depression fact sheet). Seek qualified care promptly for suicidal thoughts, self-harm, panic attacks, inability to sleep for several nights, inability to eat, severe withdrawal from life, substance misuse, hallucinations, delusions, mania-like symptoms, postpartum depression, trauma symptoms, or depression/anxiety with major medical illness (WHO depression fact sheet, WHO mental disorders fact sheet). Supplements should not be used to delay assessment when depression is severe, recurrent, bipolar-spectrum, psychotic, postpartum, or associated with suicide risk, because supplement trials largely exclude the highest-risk clinical situations and WHO explicitly recognizes medication and psychological treatment as part of care depending on severity (WHO mental disorders fact sheet).
St John’s wort, 5-HTP, “happy pills,” CBD, kava, and adaptogen blends can interact with medicines or delay effective care. Severe depression or anxiety needs professional treatment, and suicide or self-harm thoughts need urgent support.
The prevention and management stack
1) Exercise as a practical treatment adjunct
Physical activity is one of the most evidence-supported lifestyle interventions because WHO states it reduces symptoms of depression and anxiety, and the BJSM umbrella review found medium effects on depression and anxiety across adult populations (WHO physical activity fact sheet, BJSM umbrella review). For depression treatment, a 2024 BMJ network meta-analysis of 218 studies and 14,170 participants found moderate reductions for walking/jogging, yoga, strength training, mixed aerobic exercise, and tai chi/qigong, but it also warned that only one study met Cochrane low-risk-of-bias criteria, so precision should not be overstated (BMJ exercise network meta-analysis).
Practical target: choose a repeatable mix of brisk walking or jogging, resistance training, yoga or mobility, and enjoyable active recreation; the plan that is safe, sustainable, and socially supported is more valuable than a perfect plan abandoned after two weeks. WHO recommends adults do at least 150 to 300 minutes of moderate-intensity aerobic activity, or 75 to 150 minutes of vigorous-intensity activity, plus muscle-strengthening activity on two or more days weekly (WHO physical activity fact sheet).
2) Sleep: treat insomnia, not just “sleep more”
Sleep problems commonly co-occur with psychiatric disorders. The CBT-I meta-analysis cites estimates of almost 70% reporting sleep difficulties and 30% meeting insomnia criteria. Across 22 RCTs, CBT-I improved insomnia and pooled mental-health symptoms after treatment and at follow-up. Follow-up mental-health effects were not significant within diagnosis-specific pooled subgroups. CBT-I complements treatment of the psychiatric disorder. Persistent insomnia deserves assessment and targeted treatment. Source.
Practical target: fix wake time first, protect a wind-down window, avoid using the bed as a worry/work station, reduce late stimulants, and seek CBT-I when insomnia persists despite basic sleep hygiene. Sleep restriction, stimulus control, cognitive restructuring, and relapse planning are core CBT-I tools, and they should be guided when insomnia is severe, bipolar disorder is possible, or sleep deprivation worsens symptoms.
3) Nutrition: support the brain without promising food cures
Diet quality is a plausible adjunct for depression, but nutrition should be framed as support rather than a cure. The SMILES RCT found significantly greater depression-score improvement after 12 weeks of dietary support than social-support control, while a 2019 meta-analysis of 16 RCTs found dietary interventions reduced depressive symptoms but did not show an anxiety effect (SMILES RCT, diet meta-analysis).
Practical target: build meals around minimally processed foods, protein, high-fiber carbohydrates, legumes, nuts/seeds, fruits, vegetables, and omega-3-rich seafood or algae-derived alternatives when appropriate. The evidence does not support extreme elimination diets, “detoxes,” or sugar-blaming as universal mental-health treatment, and restrictive diets can worsen anxiety or disordered eating risk in vulnerable people.
4) Social connection: treat isolation as a risk factor
Social connection is not a soft add-on; a PLOS Medicine meta-analysis found social relationships predicted mortality risk, with complex social-integration measures showing the strongest association (PLOS Medicine social relationships meta-analysis). The mental-health implication is practical: depression and anxiety often shrink behavior, and a plan that includes one safe person, one predictable check-in, and one low-pressure shared activity can reduce the isolation loop even before mood fully improves.
5) Nature exposure: possible support alongside care
Nature exposure is associated with better mental-health outcomes, but systematic reviews report inconsistencies and call for better longitudinal and intervention research (life-course nature systematic review). Outdoor time may be a practical adjunct. This life-course review excluded short-term experimental studies and does not establish that a brief walk treats anxiety or depression; keep care, sleep, movement and therapy central.
6) Mindfulness and meditation: useful skills, not magic
The JAMA review found small average anxiety/depression improvements with mindfulness and moderate evidence, with lower certainty for stress outcomes. It found no superiority over active treatments and did not establish equivalence. Safety was poorly monitored. NCCIH reports that meditation can sometimes worsen anxiety or depression and advises discussing complementary practices with a health professional; specific brief-versus-long practice safety comparisons are not established. Source 1. Source 2.
The mental health management stack
Read the practical summary
- Safety and professional assessment: first priority when symptoms are severe, disabling, suicidal, psychotic, manic, postpartum, substance-related, or medically complex.
- CBT and psychotherapy skills: APA describes CBT as effective for depression and anxiety disorders (APA).
- Exercise and sleep repair: WHO states physical activity reduces depression/anxiety symptoms, and CBT-I has evidence for insomnia with mental disorders (WHO, PubMed).
- Nutrition, social connection and nature: possible supportive options, with different evidence limits; these sources do not establish a treatment benefit for every option.
- Supplements: adjuncts with interaction checks; never replacements for severe anxiety or depression care.
CBT and psychological therapies
CBT works by changing maintaining loops: catastrophic interpretation, avoidance, safety behaviors, rumination, withdrawal, and all-or-nothing problem solving. APA describes CBT as collaborative, goal-focused, and based on learning more effective coping patterns, including reevaluating distorted thoughts, facing fears instead of avoiding them, role play, relaxation, and problem-solving skills (APA CBT overview).
For anxiety, CBT often includes exposure: deliberately approaching safe but feared situations in a planned way so the nervous system learns that fear can rise and fall without avoidance. For depression, CBT often includes behavioral activation: scheduling small values-based actions before motivation returns, because waiting to “feel ready” can prolong withdrawal.
| CBT component | Best fit | What it changes | Caveat |
|---|---|---|---|
| Cognitive restructuring | Worry, guilt, hopelessness, catastrophic thoughts | Tests thoughts against evidence and alternatives. | Not enough by itself when behavior remains avoidant. |
| Exposure | Panic, social anxiety, phobias, avoidance loops | Builds inhibitory learning and confidence by safely approaching feared cues. | Should be paced and clinician-guided when trauma, dissociation, or severe impairment is present. |
| Behavioral activation | Depression, anhedonia, low energy | Restarts reward, mastery, routine, and contact with life. | Start very small; overambitious plans can backfire. |
| Problem-solving therapy | Stress from solvable practical problems | Turns vague overwhelm into actions, supports, and deadlines. | Does not replace treatment for severe mood/anxiety disorders. |
| CBT-I | Insomnia with anxiety/depression | Targets sleep scheduling, arousal, and bed-sleep conditioning. | Needs caution with bipolar-spectrum symptoms or unsafe sleep restriction. |
Medication: when it belongs in the plan
Medication can be appropriate when symptoms are moderate-to-severe, recurrent, chronic, disabling, dangerous, or not improving with therapy and lifestyle support. WHO states that medication may be considered depending on age and severity for mental disorders such as anxiety and depression, and WHO also emphasizes that effective psychological treatment exists (WHO mental disorders fact sheet).
Medication decisions should be individualized by a qualified clinician because antidepressants, anxiolytics, mood stabilizers, antipsychotics, sleep medicines, ADHD medicines, pain medicines, and hormonal treatments can interact with supplements and with each other. Never combine St John’s wort or 5-HTP with serotonergic antidepressants without clinician supervision because NCCIH warns St John’s wort plus antidepressants or other serotonin-affecting drugs may cause serious serotonin-related side effects, and 5-HTP reviews explicitly discuss serotonin syndrome safety concerns (NCCIH St John’s wort, 5-HTP review).
Supplements: useful adjuncts, not replacements
Supplements should answer three questions before use: what symptom is being targeted, what evidence supports that exact ingredient/form, and what medicines or conditions could make it unsafe. The safest editorial position is conservative: severe symptoms need professional care first; supplements can be considered for mild symptoms, residual symptoms, deficiency correction, or short-term stress support only after interaction screening.
| Supplement | Best-supported role | Evidence note | Main safety issue | Verdict |
|---|---|---|---|---|
| Omega-3 supplements | Adjunct for depressive symptoms in some people; stronger general evidence for triglycerides than mood. | Cochrane says high-certainty evidence is insufficient for major depression; NCCIH says any depression effect may be too small to be meaningful. | GI effects, fish allergy, anticoagulant/antiplatelet caution, possible atrial fibrillation concern at high doses. | Mixed adjunct Cochrane / NIH ODS |
| Magnesium | Possible anxiety/stress support when intake is low or vulnerability exists. | The cited systematic review found suggestive anxiety benefit with poor-quality evidence; it does not establish a depression-treatment effect. | Diarrhea, cramping, nausea; toxicity risk with kidney disease; reduces absorption of some antibiotics and bisphosphonates. | Suggestive magnesium anxiety review / NIH ODS magnesium |
| Vitamin D | Correct deficiency for bone and general health; not a proven depression-prevention supplement in sufficient older adults. | VITAL-DEP found vitamin D3 did not significantly reduce depression risk or mood scores over median 5.3 years. | Excess can cause hypercalcemia, kidney stones, nausea, weakness, and drug interactions. | Correct deficiency, not mood cure VITAL-DEP / NIH ODS vitamin D |
| Ashwagandha | Short-term stress or insomnia support with selected preparations. | NCCIH says some preparations may be effective for insomnia and stress, but long-term safety is not established. | GI upset, drowsiness, liver injury reports, pregnancy caution, possible thyroid/immune/sedative interactions. | Promising but safety-limited NCCIH |
| L-theanine | Acute stress/anxiety support, often 200–400 mg/day in trials. | The nine-study review found mixed short-term stress-response signals. Its 46-person GAD trial, using 450–900 mg/day, showed no anxiety or mood advantage over placebo; larger and longer trials remain necessary. | Limited long-term and interaction data; seek medication advice. The cited review does not demonstrate a clinical sedative or blood-pressure-drug interaction. | Preliminary short-term stress evidence L-theanine review |
| Saffron | Adjunct for mild-to-moderate depressive symptoms. | Small trials suggest benefit over placebo; pooled drug-comparison results did not show a statistically significant difference. This does not establish noninferiority or equivalence. | Short-term adverse-event evidence does not settle long-term safety or drug interactions; seek professional advice. | Promising saffron meta-analysis Source 1 Source 2 |
| St John’s wort | Mild-to-moderate depression only when interaction risk is professionally checked. | Cochrane found benefit vs placebo and similar effects to antidepressants in trials; NCCIH warns severe interactions. | Serotonin syndrome risk with serotonergic drugs; reduces effectiveness of many medicines through CYP/P-gp induction; photosensitivity and GI/neurologic effects. | Effective but high-risk Cochrane / interaction review |
Supplement evidence versus safety map
Read the practical summary
| Ingredient | Evidence position | Safety burden |
|---|---|---|
| St John’s wort | Better evidence for mild-to-moderate depression than many herbs. | Documented serious interactions; NCCIH warns serotonin-related interactions can be serious and drug-effect reductions can occur (NCCIH). |
| Ashwagandha | Some evidence for stress/insomnia. | Long-term safety uncertain; rare liver injury reports exist (NCCIH). |
| Saffron | Promising depression meta-analyses. | Moderate safety uncertainty; more independent long-term trials needed (PubMed). |
| L-theanine | Suggestive for stress/anxiety under stressful conditions. | Interactions have not been comprehensively tested; limited longer-term safety data (PubMed). |
| Omega-3 EPA | Mixed depression evidence; strong non-mood uses not covered here. | Bleeding/anticoagulant and high-dose safety checks needed (NIH ODS). |
| Magnesium and vitamin D | Most useful when correcting low intake/status; direct mood evidence is mixed. | Magnesium requires kidney and drug-absorption checks; vitamin D requires hypercalcemia and drug checks (NIH ODS magnesium, NIH ODS vitamin D). |
All forms and grades
| Form / type | Examples | Best for | Evidence grade | Key caveat |
|---|---|---|---|---|
| Urgent/crisis care | Emergency care, crisis line, urgent psychiatric assessment, safe supervision | Suicidal thoughts, self-harm, psychosis, mania, severe impairment | Essential safety care | Do not wait for lifestyle or supplements to work. |
| Assessment and diagnosis | Primary care, psychiatry, psychology, validated symptom scales, medical rule-outs | Persistent or unclear symptoms | Core | Thyroid disease, anemia, sleep apnea, substance use, medication effects, pain, and trauma can mimic or worsen symptoms. |
| Psychotherapy | CBT, exposure therapy, behavioral activation, interpersonal therapy, trauma-focused therapy, CBT-I | Most anxiety/depression patterns | Strong | Match therapy to problem; generic supportive talk may not treat avoidance or insomnia loops. |
| Medication | SSRIs/SNRIs, other antidepressants, anxiolytics, sleep treatments, mood stabilizers when indicated | Moderate-to-severe, recurrent, disabling, or high-risk symptoms | Strong when indicated | Requires clinician selection, monitoring, and interaction checks. |
| Exercise | Walking/jogging, strength training, yoga, tai chi/qigong, mixed aerobic activity | Adjunct management and prevention support | Strong adjunct | Start below capacity if deconditioned, ill, pregnant, injured, or medically unstable. |
| Sleep interventions | CBT-I, consistent wake time, stimulus control, sleep restriction with guidance | Insomnia with anxiety/depression | Strong for insomnia | Sleep restriction needs caution in bipolar-spectrum symptoms. |
| Nutrition | Mediterranean-style or whole-diet improvement, protein adequacy, fiber, omega-3 foods, deficiency correction | Depression support, energy stability, cardiometabolic health | Moderate adjunct | Avoid rigid “mental health diet” claims. |
| Social and environmental support | Peer support, family involvement, group activities, workplace/school adjustments, nature time | Isolation, stress load, relapse prevention | Moderate/indirect | Unsafe relationships require boundaries, not more exposure. |
| Mind-body practices | Mindfulness, breath training, relaxation, yoga, tai chi | Stress regulation and anxiety symptoms | Moderate adjunct | Not always best for trauma/panic without guidance. |
| Supplements | EPA-rich omega-3, magnesium, vitamin D, ashwagandha, L-theanine, saffron, St John’s wort | Selected mild symptoms, deficiencies, short-term support | Mixed | Interactions can be serious; St John’s wort has multiple documented drug interactions. |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| “Exercise helps depression and anxiety.” | WORKS as an adjunct | WHO, BJSM umbrella review, Cochrane depression review. | Not a substitute for urgent care or severe depression treatment. |
| “CBT helps anxiety and depression.” | WORKS | APA describes broad effectiveness and improved functioning. | Requires skilled matching and practice between sessions. |
| “Sleep hygiene alone fixes depression.” | MIXED | CBT-I evidence is stronger than generic sleep tips. | Persistent insomnia often needs CBT-I, medical evaluation, or both. |
| “Diet can support mood.” | WORKS modestly for depression support | SMILES RCT and diet meta-analysis. | Evidence is weaker for anxiety and not a replacement for care. |
| “Mindfulness reduces stress.” | WORKS modestly | The JAMA review found small anxiety/depression improvements with moderate certainty and small stress/distress improvements with low certainty. | Not clearly superior to active treatments. |
| “Supplements can cure anxiety or depression.” | DOESN’T | No supplement has evidence to replace professional treatment for severe anxiety/depression. | Risk rises when supplements delay care. |
| “St John’s wort is safe because it is natural.” | DOESN’T | NCCIH and interaction reviews document serious drug-interaction potential. | Avoid with serotonergic medicines and many other drugs unless a clinician/pharmacist clears it. |
| “Vitamin D prevents depression in everyone.” | DOESN’T | VITAL-DEP found no prevention effect in adults aged 50+ over 5.3 years. | Correct deficiency for health; do not sell it as a mood cure. |
What works versus what does not
Read the practical summary
| Category | Items | Evidence notes |
|---|---|---|
| Works | CBT, exercise as adjunct, CBT-I for insomnia, urgent care when safety risk exists. | Supported by APA, WHO, Cochrane/BMJ, and PubMed-indexed meta-analysis evidence. |
| Mixed | Nutrition, mindfulness, omega-3 for major depression, magnesium for anxiety. | Signals exist, but effect size, bias, deficiency status, and clinical relevance vary. |
| Doesn’t | Supplements as cures, vitamin D for universal depression prevention, homeopathy for anxiety, delaying care when severe. | Evidence is insufficient, negative, or outweighed by safety risk. |
Risks and all side effects
| Ingredient / intervention | Common side effects or problems | Rare but serious risks | At-risk groups | Source |
|---|---|---|---|---|
| Exercise | Soreness, fatigue, injury if progressed too fast. | Risk depends on intensity, progression and health status; the cited WHO fact sheet does not quantify serious-event rates. | Seek individualized advice before starting or intensifying exercise with significant illness, concerning symptoms or pregnancy complications; build activity gradually. | WHO physical activity |
| Meditation / mindfulness | Negative experiences, including increased anxiety or depression, have been reported. | Few studies systematically examined harm; rare-risk frequencies and vulnerable groups remain uncertain. | People whose symptoms worsen should discuss or adapt practice with their clinician. | NCCIH meditation safety guidance Source |
| Omega-3 EPA/DHA | Fishy aftertaste, bad breath, heartburn, nausea, loose stool. | Bleeding concerns at high doses or with anticoagulants/antiplatelets; possible atrial fibrillation concern in high-dose trials. | Fish/shellfish allergy, bleeding disorders, anticoagulant/antiplatelet users, planned surgery, atrial fibrillation history. | NIH ODS omega-3 |
| Magnesium supplements | Diarrhea, nausea, abdominal cramping. | Magnesium toxicity with high supplemental doses, especially kidney impairment. | Kidney disease, older adults using multiple medicines, people using interacting antibiotics or bisphosphonates. | NIH ODS magnesium |
| Vitamin D | Nausea, constipation, weakness, excess thirst/urination when too high. | Hypercalcemia, kidney stones, kidney injury, arrhythmia risk when calcium is high. | People with high calcium, kidney disease, thiazide use or high combined calcium/vitamin D intake should review supplementation with a clinician. | NIH ODS vitamin D |
| Ashwagandha | Digestive upset, diarrhea, nausea, vomiting, drowsiness. | Liver injury; NCCIH notes rare liver injury cases and insufficient long-term safety data. | Pregnancy, liver disease, autoimmune disease, thyroid disorders, sedative users, immunosuppressant users. | NCCIH ashwagandha / liver injury case series |
| L-theanine | Short trials did not establish a consistent excess of adverse events; common side-effect frequencies and long-term safety remain uncertain. | Unclear due to limited long-term human safety evidence. | Pregnancy/lactation and concurrent medicines require professional advice because safety and interaction data are limited; a clinical sedative interaction was not established by this review. | L-theanine review |
| Saffron | Small short-term trials did not show a significant overall adverse-event difference from placebo or antidepressants. | Long-term, high-dose and rare-event safety remain uncertain. | Pregnancy, complex illness or concurrent psychiatric medicines require professional advice; specific interactions are not established by this review. | saffron safety review Source |
| St John’s wort | Diarrhea, dizziness, trouble sleeping, restlessness, skin tingling, photosensitivity. | Serious serotonin-related interactions with serotonergic drugs and reduced effectiveness of many medicines. Mania-like episodes appear in interaction case reports; incidence and attribution are uncertain. | Anyone using antidepressants, oral contraceptives, anticoagulants, immunosuppressants, HIV medicines, cancer medicines, transplant medicines, seizure medicines, or bipolar-spectrum history. | NCCIH St John’s wort / interaction review |
All interactions
| Interacts with | Ingredient / support | Severity | Mechanism / effect | Action |
|---|---|---|---|---|
| SSRIs, SNRIs, MAOIs, tricyclics, mirtazapine, trazodone, triptans, tramadol, linezolid, lithium, MDMA or other serotonergic substances | St John’s wort; precautionary review for 5-HTP | Avoid unless clinician-directed | NCCIH warns that St John’s wort plus serotonin-affecting drugs can cause serious side effects. The 2005 5-HTP review described a theoretical risk; specific saffron interactions are not established. | Do not combine without clinician/pharmacist clearance. |
| Oral contraceptives, HIV medicines, transplant immunosuppressants, warfarin/DOACs, anti-seizure medicines, digoxin, some cancer medicines, many antidepressants | St John’s wort | Avoid | Induces CYP enzymes and P-glycoprotein, lowering drug levels and efficacy. | Use only with professional medication review; often avoid entirely. |
| Anticoagulants and antiplatelets: warfarin, DOACs, aspirin, clopidogrel; planned surgery | Omega-3 and St John’s wort; saffron interactions remain insufficiently studied | Caution/monitor | St John’s wort can reduce anticoagulant exposure or effect. Omega-3 warrants dose-specific medication review, although the NIH review did not establish clinically significant bleeding overall. The cited saffron review does not establish a bleeding interaction. | Discuss dose and timing with clinician before use. |
| Tetracycline and quinolone antibiotics; bisphosphonates; levothyroxine timing-sensitive regimens | Magnesium | Separate doses | Mineral binding reduces medicine absorption. | Separate by clinician/pharmacist instructions; do not take together. |
| Kidney disease or severe dehydration | Magnesium; vitamin D; high-dose supplements | Medical supervision | Reduced clearance raises toxicity risk; vitamin D can worsen high calcium. | Avoid unsupervised supplementation. |
| Thiazide diuretics, digoxin, high-dose calcium | Vitamin D | Caution/monitor | Hypercalcemia risk; calcium changes can worsen digoxin toxicity risk. | Use lab-guided supplementation. |
| Sedatives, benzodiazepines, Z-drugs, opioids, alcohol, sleep herbs | Ashwagandha, kava and CBD; L-theanine interactions remain insufficiently studied | Caution/avoid mixing | Kava, CBD and ashwagandha can cause drowsiness or interact with sedatives. The L-theanine review does not demonstrate additive sedation or respiratory/CNS depression from such combinations. | Avoid alcohol/sedative stacking; ask clinician if taking CNS depressants. |
| Thyroid medication or thyroid disease | Ashwagandha | Caution | Possible thyroid hormone effects; case reports and mechanistic concern. | Use only with monitoring if thyroid disease or thyroid medicine is present. |
| Immunosuppressants, autoimmune disease treatments | Ashwagandha | Caution/avoid | Potential immune-modulating effects could oppose immunosuppressive therapy. | Ask treating clinician before use. |
| Liver disease or hepatotoxic medicines | Ashwagandha, kava, CBD, high-dose multi-ingredient blends | Avoid unless clinician-directed | Rare liver injury reports and additive liver burden. | Avoid self-supplementing; seek medical advice if jaundice, dark urine, itching, or right-upper-abdominal pain occurs. |
| Pregnancy, lactation, trying to conceive | St John’s wort, ashwagandha, kava, high-dose saffron, 5-HTP, CBD | Avoid unless clinician-directed | Safety uncertainty or specific pregnancy concerns. | Use only pregnancy-qualified medical advice. |
Red-flag supplement interactions
Read the practical summary
- St John’s wort: avoid with serotonergic drugs and critical medicines unless a clinician/pharmacist clears the combination, because it can increase serotonin-related side effects and lower drug levels (NCCIH, PubMed interaction review).
- Magnesium: separate from tetracycline/quinolone antibiotics and bisphosphonates because minerals can reduce medicine absorption (NIH ODS).
- Blood thinners: discuss omega-3 dose and medication monitoring. The cited saffron review does not establish a bleeding interaction.
- Ashwagandha, kava and CBD: avoid sedative stacking. L-theanine combination effects have not been adequately tested; seek medication advice.
- Pregnancy, liver disease, kidney disease, bipolar symptoms: require clinical review before supplements.
Frequently asked questions
What is a practical evidence-based starting plan?
Start with a safety and support plan: seek professional care when symptoms are severe or impairing, add manageable daily movement, maintain a regular wake time, reduce avoidance and tell a trusted person what is happening. Exercise and CBT-style action may help, but urgent safety concerns should not wait for self-care; contact local emergency or crisis services if there is immediate danger. Source 1. Source 2. Source 3.
Can stress turn into anxiety or depression?
Stressful events can increase depression risk, and WHO notes that people who have lived through abuse, severe losses, or other stressful events are more likely to develop depression (WHO depression fact sheet). Chronic stress can also keep the body’s alarm system active and affect many body systems, which is why recovery, social support, and professional care matter when stress becomes persistent or impairing (APA stress effects).
Is CBT better than medication?
CBT and medication are not rivals; the best choice depends on severity, diagnosis, preference, access, risk, and past response. APA states CBT has been shown in many studies to be as effective as or more effective than other psychological therapies or psychiatric medications in many contexts, while WHO notes medication may be considered depending on age and severity (APA CBT overview, WHO mental disorders fact sheet).
Which supplement has the strongest evidence?
St John’s wort has a depression benefit signal, but documented serious interactions require clinician and pharmacist review. Saffron and L-theanine have limited adjunct evidence; their small studies do not establish a universally lower interaction burden or safe replacement for care. Magnesium and vitamin D decisions should reflect nutritional status and clinical needs. Source 1. Source 2. Source 3.
Can I take St John’s wort with an antidepressant?
No, not without clinician and pharmacist clearance. NCCIH warns that St John’s wort with antidepressants or other drugs that affect serotonin may lead to serious serotonin-related side effects, and interaction reviews document clinically important pharmacokinetic interactions through CYP enzymes and P-glycoprotein (NCCIH St John’s wort, St John’s wort interaction review).
Does vitamin D help depression?
Vitamin D should be corrected when deficiency is present, but it should not be marketed as a universal depression-prevention supplement. VITAL-DEP found vitamin D3 did not significantly reduce incident or recurrent depression or mood scores over a median 5.3 years in adults aged 50+ without clinically relevant depressive symptoms at baseline (VITAL-DEP).
Is ashwagandha safe for stress?
Ashwagandha may help stress or insomnia for some people, but NCCIH says long-term safety is not established and rare liver injury cases have been reported (NCCIH ashwagandha). Avoid unsupervised use in pregnancy, liver disease, autoimmune disease, thyroid disorders, sedative use, or immunosuppressant therapy.
What should I do if I am too depressed to exercise?
Start with behavioral activation, not motivation: one minute outside, one shower, one message to a trusted person, or one five-minute walk counts as treatment momentum. If depression causes inability to function, eat, sleep, work, study, care for dependents, or stay safe, professional care should come first because WHO states effective treatments exist for depression across severity levels (WHO depression fact sheet).
Sources
- WHO — Depressive disorder (depression)
- WHO — Anxiety disorders
- WHO — Mental disorders
- WHO — Physical activity
- APA — Stress effects on the body
- APA — What is Cognitive Behavioral Therapy?
- Cochrane — Exercise for depression
- Noetel et al. Exercise for depression. BMJ. 2024.
- Singh et al. Physical activity interventions for depression, anxiety and distress. BJSM. 2023.
- Goyal et al. Meditation programs for psychological stress and well-being. JAMA Internal Medicine. 2014. PubMed
- Cochrane — St John’s wort for treating depression
- NCCIH — St John’s Wort: Usefulness and Safety
- Cochrane — Omega-3 fatty acids for depression in adults
- Boyle et al. Magnesium supplementation for subjective anxiety and stress. PubMed
- Okereke et al. Vitamin D3 and depression risk, VITAL-DEP. PubMed
- NCCIH — Ashwagandha: Usefulness and Safety
- Williams et al. L-theanine stress and anxiety systematic review. PubMed
- Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. 2013. Manufacturer-funded review; adviser/consultant ties disclosed. Source.
- Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, Tenk J, Pétervári E, Balaskó M, Rumbus Z, Rakonczay Z, Bálint ER, Kiss T, Csupor D. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. 2019. Research record
- NIH ODS — Magnesium fact sheet
- NIH ODS — Vitamin D fact sheet
- NIH ODS — Omega-3 fatty acids fact sheet
- Philips et al. Ashwagandha-induced liver injury case series. PMC
- Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Safety. 2004. Source.
- Holt-Lunstad et al. Social relationships and mortality risk. PLOS Medicine / PMC
- Li D, Menotti T, Ding Y, Wells NM. Life Course Nature Exposure and Mental Health Outcomes: A Systematic Review and Future Directions. 2021. Research record
- Hertenstein et al. CBT-I in mental disorders meta-analysis. PubMed
- Jacka et al. SMILES dietary intervention RCT. PMC
- Firth et al. Dietary improvement for depression and anxiety meta-analysis. PubMed
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
Research funding at a glance
9 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.